2 ultrasound AI systems cleared for market

The FDA has approved an AI tool for speeding thyroid sonography workflows while, across the big pond, the European Union has OK’d an AI-based ultrasound device that guides nerve blocking as a form of local anesthesia.

Edmonton-based Medo announced the U.S. go-ahead for its Medo-Thyroid May 6. The product uses algorithms to automatically review scans of the thyroid gland, calculating relevant measurements and classifying any nodules with the American College of Radiology’s TI-RADS system.  

The company says the product breaks new technological ground with various features, including a module for cross-referencing exams from various imaging modalities.

Meanwhile U.K.-based Intelligent Ultrasound Group earned CE Mark status in April for its ScanNav PNB, which supports nine common peripheral nerve blocks.

The company says the product plugs in to anesthesiology ultrasound machines and will be sold as a standalone device with embedded AI software.

Intelligent Ultrasound also says it’s currently working toward FDA approval and will seek to integrate ScanNav in ultrasound machines from various manufacturers.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.